Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-powered drug discovery in collaboration with the University of British Columbia and the Vancouver Prostate Centre [1][2][5] Collaboration and Infrastructure - The partnership with UBC and the Vancouver Prostate Centre allows for compound testing and validation in a leading cancer research facility, enhancing the translation of scientific discoveries [2][5] - Rakovina's management team and scientific advisory board members hold dual roles at UBC and the Vancouver Prostate Centre, strengthening the collaboration [3] Key Personnel - Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, serves as an Associate Professor at UBC and leads Molecular Pathology at the Vancouver Prostate Centre, bridging cancer biology with Rakovina's drug discovery programs [3] - Dr. Artem Cherkasov, AI and medicinal chemistry advisor, is a Senior Research Scientist at the Vancouver Prostate Centre and a Professor at UBC, known for developing the Deep Docking™ platform that accelerates drug discovery [4] Strategic Alignment - The company emphasizes strategic alignment with UBC's research excellence, leveraging infrastructure and expertise to advance next-generation cancer therapies [5] - Rakovina Therapeutics is focused on developing a pipeline of DNA-damage response inhibitors, aiming to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [6][7]